# Carmot Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/carmot-therapeutics

- Industry: Biotechnology
- Headquarters: Berkeley, US
- Website: www.carmot.us
- Total disclosed funding: $367M
- Latest round: Series E (May 24, 2023)
- Investors on record: 14

## About

Carmot Therapeutics, Inc. is a biotechnology company focused on innovative drug discovery and development using its proprietary platform to enhance therapeutic strategies for various diseases.Founded in 2008 and headquartered in Berkeley, US, Carmot Therapeutics, Inc. specializes in drug discovery and development. The company was established by Stig Hansen and has undergone significant transformations in its operational strategies. The company has engaged in 11 deals, with the most recent deal occurring on December 3, 2023. Carmot Therapeutics raised a total of USD 151.70 mn, with its latest funding round being an Add-on at USD 2.70 bn, led by Roche.Carmot Therapeutics focuses on advancing drug discovery through its innovative platform that leverages unique screening technologies. Their services aim to identify and optimize small molecules for various therapeutic targets, providing solutions that facilitate the development of novel pharmaceuticals. This includes work on cardiovascular and metabolic diseases, with a keen emphasis on enhancing R&D processes for pharmaceutical companies.For the year 2022, Carmot Therapeutics reported an EBITDA of USD -42.79 mn, reflecting the company's ongoing investment in research and development.Looking ahead, Carmot Therapeutics plans to leverage the recent acquisition by F. Hoffmann-La Roche Ltd to enhance its research and development capabilities. The acquisition is intended to strengthen Roche's portfolio in cardiovascular and metabolic diseases, with an additional USD 400 mn available upon achieving specific milestones. This strategic move is anticipated to expand Carmot's reach in new markets, particularly in North America and Europe, as it continues to develop clinical-stage incretin programs.

## Funding rounds

- Series E, May 24, 2023, $152M — Schroders Capital, Frazier Healthcare Partners, Venrock, 5AM Ventures, The Column Group, Millennium Management, Willett Advisors, RA Capital Management, Franklin Templeton, Janus Henderson Investors, TCG Crossover Management, Deep Track Capital
- Series D, Jul 25, 2022, $161M — The Column Group, Willett Advisors, Horizons Ventures, RA Capital Management, Deep Track Capital
- Series C, Sep 17, 2020, $26M — The Column Group, Horizons Ventures, Amgen Inc.
- Series B, Jan 17, 2018, $15M — The Column Group, Horizons Ventures
- Series B, Aug 11, 2017, $11M — The Column Group
- Series A, Jul 17, 2012, $0.5M — The Column Group
- Series A, Apr 12, 2010, $1.6M — The Column Group

## Investors

- The Column Group (https://capitalatlas.ai/funds/the-column-group) — Series A, Series B, Series C, Series D, Series E
- Horizons Ventures — Series B, Series C, Series D
- Amgen Inc. — Series C
- Willett Advisors — Series D, Series E
- RA Capital Management (https://capitalatlas.ai/funds/ra-capital-management) — Series D, Series E
- Deep Track Capital (https://capitalatlas.ai/funds/deep-track-capital) — Series D, Series E
- Schroders Capital (https://capitalatlas.ai/funds/schroders-capital) — Series E
- Frazier Healthcare Partners (https://capitalatlas.ai/funds/frazier-healthcare-partners) — Series E
- Venrock (https://capitalatlas.ai/funds/venrock) — Series E
- 5AM Ventures (https://capitalatlas.ai/funds/5am-ventures) — Series E
- Millennium Management — Series E
- Franklin Templeton (https://capitalatlas.ai/funds/franklin-templeton) — Series E
- Janus Henderson Investors — Series E
- TCG Crossover Management (https://capitalatlas.ai/funds/tcg-crossover-management) — Series E